Trial of Deferiprone in Parkinson’s DiseaseShow More
The New England Journal of Medicine , Volume 387, pp 2045-2055; https://doi.org/10.1056/nejmoa2209254
Abstract: Iron content is increased in the substantia nigra of persons with Parkinson’s disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson’s disease, but its effects on disease progression are unclear.
Keywords: Parkinson / deferiprone / nigra / chelator / pathophysiology / nigrostriatal / substantia / Disease Iron / iron content
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Click here to see the statistics on "The New England Journal of Medicine" .